JPWO2023092057A5 - - Google Patents

Info

Publication number
JPWO2023092057A5
JPWO2023092057A5 JP2024529579A JP2024529579A JPWO2023092057A5 JP WO2023092057 A5 JPWO2023092057 A5 JP WO2023092057A5 JP 2024529579 A JP2024529579 A JP 2024529579A JP 2024529579 A JP2024529579 A JP 2024529579A JP WO2023092057 A5 JPWO2023092057 A5 JP WO2023092057A5
Authority
JP
Japan
Prior art keywords
oligomeric compound
modified
modified oligonucleotide
internucleoside linkage
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540537A (ja
JP2024540537A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080113 external-priority patent/WO2023092057A1/en
Publication of JP2024540537A publication Critical patent/JP2024540537A/ja
Publication of JPWO2023092057A5 publication Critical patent/JPWO2023092057A5/ja
Publication of JP2024540537A5 publication Critical patent/JP2024540537A5/ja
Pending legal-status Critical Current

Links

JP2024529579A 2021-11-18 2022-11-18 プログラニュリン発現を調節するための化合物及び方法 Pending JP2024540537A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163281057P 2021-11-18 2021-11-18
US63/281,057 2021-11-18
PCT/US2022/080113 WO2023092057A1 (en) 2021-11-18 2022-11-18 Compounds and methods for modulating progranulin expression

Publications (3)

Publication Number Publication Date
JP2024540537A JP2024540537A (ja) 2024-10-31
JPWO2023092057A5 true JPWO2023092057A5 (https=) 2025-11-06
JP2024540537A5 JP2024540537A5 (https=) 2025-11-06

Family

ID=86397858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529579A Pending JP2024540537A (ja) 2021-11-18 2022-11-18 プログラニュリン発現を調節するための化合物及び方法

Country Status (4)

Country Link
US (1) US20250109396A1 (https=)
EP (1) EP4433591A1 (https=)
JP (1) JP2024540537A (https=)
WO (1) WO2023092057A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260051070A (ko) 2023-08-10 2026-04-15 하네스 테라퓨틱스 리미티드 기능적 핵산
WO2025104638A1 (en) * 2023-11-17 2025-05-22 Universita' Degli Studi Di Brescia Antisense oligonucleotides for modulation of progranulin splicing
GB202401412D0 (en) 2024-02-02 2024-03-20 Harness Therapeutics Ltd Functional nucleic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2520935A3 (en) * 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CN106967799A (zh) * 2017-03-24 2017-07-21 杭州艾迪康医学检验中心有限公司 检测btk基因突变的方法、寡核苷酸及其应用
US12595479B2 (en) * 2019-03-20 2026-04-07 President And Fellows Of Harvard College Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
TW202208628A (zh) * 2020-05-13 2022-03-01 瑞士商赫孚孟拉羅股份公司 靶向顆粒蛋白前體之寡核苷酸促效劑

Similar Documents

Publication Publication Date Title
JP2009067805A (ja) 中枢神経系へのポリヌクレオチド薬剤の送達
JP2010090159A (ja) 腫瘍の治療における、ＴＧＦ−β、ＶＥＧＦ、インターロイキン−１０、Ｃ−ＪＵＮ、Ｃ−ＦＯＳまたはプロスタグランジンＥ２遺伝子にアンチセンスなオリゴヌクレオチドの低適用量の使用
CA2357950C (en) Therapeutic phosphodiesterase inhibitors
CN120129749A (zh) 靶向微管相关蛋白TAU核酸的siRNA组合物和方法
JPWO2023092057A5 (https=)
JPWO2020106996A5 (https=)
JPWO2022246251A5 (https=)
CA3269248A1 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS
JPWO2022026589A5 (https=)
CN120129748A (zh) 靶向α-突触核蛋白核酸的siRNA组合物和方法
AU2023354010A1 (en) Compositions and methods for treatment of neurodegenerative diseases
US20260098269A1 (en) Compositions and methods for treatment of neuroinflammatory diseases
JPWO2020055917A5 (https=)
JP2025518230A (ja) モノアミン酸化酵素ｂに対するアンチセンスオリゴマー及びその用途
TW202511482A (zh) 新穎之SCN10A RNAi藥劑及其用途
WO2026009916A1 (ja) ２本鎖オリゴヌクレオチド
KR20250076771A (ko) Kcnq4의 발현을 조절하는 안티센스 화합물
JP2024531363A (ja) Ｃａｖ３．１遺伝子を標的とするアンチセンスオリゴヌクレオチド及びその使用
TW202604552A (zh) 用於降低atxn3表達之修飾寡核苷酸
CN120641565A (zh) 用于治疗基于无义介导的rna衰变的病状和疾病的反义寡聚物
WO2023102490A1 (en) Compositions and methods for treatment of epilepsies
JP2026509929A (ja) 改善された遺伝子サイレンシングのための組成物及び方法
JP2025517248A (ja) ＳＣＮ１Ａ発現カセットのＣＡＶ－２媒介送達を介して外因性Ｎａｖ１．１活性を提供するためのベクター、組成物、及び方法
JPWO2022066956A5 (https=)
JPWO2022006134A5 (https=)